MedPath
Found 1424 clinical trials|View Analysis
Sort by:

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3
Not yet recruiting
Conditions
HER2-positive Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Interventions
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
AstraZeneca
Target Recruit Count
840
Registration Number
NCT06764875
Locations
🇻🇳

Research Site, Vinh, Vietnam

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

First Posted Date
2024-12-27
Last Posted Date
2024-12-27
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
700
Registration Number
NCT06750094
Locations
🇺🇸

Cancer and Blood Specialty Clinic, Los Alamitos, California, United States

🇺🇸

Providence Medical Foundation, Santa Rosa, California, United States

🇦🇺

Concord Hospital, Concord, Australia

and more 11 locations

Intraoperative 5-fluorouracil Augmentation of Trabeculectomy

Phase 3
Completed
Conditions
Glaucoma
Primary Open Angle Glaucoma
Interventions
First Posted Date
2024-12-20
Last Posted Date
2024-12-20
Lead Sponsor
Moorfields Eye Hospital NHS Foundation Trust
Target Recruit Count
368
Registration Number
NCT06745856

Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma

Phase 1
Not yet recruiting
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Drug: Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin
First Posted Date
2024-12-18
Last Posted Date
2024-12-18
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
10
Registration Number
NCT06741020
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children with Palmoplantar Wart

Not Applicable
Not yet recruiting
Conditions
Common Warts
Interventions
First Posted Date
2024-12-17
Last Posted Date
2024-12-17
Lead Sponsor
Mazandaran University of Medical Sciences
Target Recruit Count
60
Registration Number
NCT06737406
Locations
🇮🇷

Iran, Sari, Mazandaran, Iran, Islamic Republic of

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

First Posted Date
2024-12-13
Last Posted Date
2024-12-16
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
238
Registration Number
NCT06733038
Locations
🇮🇹

Istituto Oncologico Veneto Irccs, Padova, PD, Italy

🇮🇹

Nuovo Ospedale di Prato S. Stefano, Prato, PO, Italy

🇮🇹

U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

Phase 2
Not yet recruiting
Conditions
Locally Advanced Thyroid Gland Carcinoma
Thyroid Cancer
Interventions
First Posted Date
2024-12-03
Last Posted Date
2024-12-03
Lead Sponsor
West China Hospital
Target Recruit Count
20
Registration Number
NCT06713057
Locations
🇨🇳

West China hospital, Chengdu, Sichuan, China

Carac & PDT Combination in the Treatment Of Actinic Keratoses

Phase 1
Completed
Conditions
Actinic Keratoses
Interventions
Drug: Fluorouracil
Procedure: Photodynamic therapy
Procedure: Carac in combination with PDT
First Posted Date
2024-12-02
Last Posted Date
2024-12-02
Lead Sponsor
Skin Laser & Surgery Specialists
Target Recruit Count
60
Registration Number
NCT06712381

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene

Phase 1
Not yet recruiting
Conditions
Carcinoma, Pancreatic Ductal
Colorectal Neoplasms
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: PF-07985045
Combination Product: Gemcitabine
Combination Product: Cetuximab
Combination Product: Fluorouracil
Combination Product: Pembrolizumab
Combination Product: PF-07284892
Combination Product: Nab-paclitaxel
Combination Product: Oxaliplatin
Combination Product: Sasanlimab
Combination Product: pemetrexed
Combination Product: Leucovorin
Combination Product: Cisplatin
Combination Product: Bevacizumab
Combination Product: Paclitaxel
Combination Product: Carboplatin
First Posted Date
2024-11-26
Last Posted Date
2024-12-10
Lead Sponsor
Pfizer
Target Recruit Count
230
Registration Number
NCT06704724

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2024-11-25
Last Posted Date
2024-11-25
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Target Recruit Count
876
Registration Number
NCT06703177
Locations
🇨🇳

Sun Yat-Sen university cancer center, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath